1 3864 147 JAK-STAT PATHWAY INHIBITION PARTIALLY RESTORES INTESTINAL HOMEOSTASIS IN HDAC1- AND HDAC2-INTESTINAL EPITHELIAL CELL-DEFICIENT MICE. WE HAVE PREVIOUSLY REPORTED THAT HISTONE DEACETYLASE EPIGENETIC REGULATOR HDAC1 AND HDAC2 DELETION IN INTESTINAL EPITHELIAL CELLS (IEC) DISRUPTS MUCOSAL TISSUE ARCHITECTURE AND BARRIER, CAUSING CHRONIC INFLAMMATION. IN THIS STUDY, PROTEOME AND TRANSCRIPTOME ANALYSIS REVEALED THE IMPORTANCE OF SIGNALING PATHWAYS INDUCED UPON GENETIC IEC-HDAC1 AND HDAC2 DELETION. INDEED, GENE ONTOLOGY BIOLOGICAL PROCESS ANALYSIS OF ENRICHED DEFICIENT IEC RNA AND PROTEINS IDENTIFIED COMMON PATHWAYS, INCLUDING LIPID METABOLIC AND OXIDATION-REDUCTION PROCESS, CELL ADHESION, AND ANTIGEN PROCESSING AND PRESENTATION, RELATED TO IMMUNE RESPONSES, CORRELATING WITH DYSREGULATION OF MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS II GENES. TOP UPSTREAM REGULATORS INCLUDED REGULATORS ASSOCIATED WITH ENVIRONMENTAL SENSING PATHWAYS TO XENOBIOTICS, MICROBIAL AND DIET-DERIVED LIGANDS, AND ENDOGENOUS METABOLITES. PROTEOME ANALYSIS REVEALED MTOR SIGNALING IEC-SPECIFIC DEFECTS. IN ADDITION TO MTOR, THE STAT AND NOTCH PATHWAYS WERE DYSREGULATED SPECIFICALLY IN JEJUNAL IEC. TO DETERMINE THE IMPACT OF PATHWAY DYSREGULATION ON MUTANT JEJUNUM ALTERATIONS, WE TREATED MUTANT MICE WITH TOFACITINIB, A JAK INHIBITOR. TREATMENT WITH THE INHIBITOR PARTIALLY CORRECTED PROLIFERATION AND TIGHT JUNCTION DEFECTS, AS WELL AS NICHE STABILIZATION BY INCREASING PANETH CELL NUMBERS. THUS, IEC-SPECIFIC HISTONE DEACETYLASES 1 (HDAC1) AND 2 (HDAC2) SUPPORT INTESTINAL HOMEOSTASIS BY REGULATING SURVIVAL AND TRANSLATION PROCESSES, AS WELL AS DIFFERENTIATION AND METABOLIC PATHWAYS. HDAC1 AND HDAC2 MAY PLAY AN IMPORTANT ROLE IN THE REGULATION OF IEC-SPECIFIC INFLAMMATORY RESPONSES BY CONTROLLING, DIRECTLY OR INDIRECTLY, THE JAK/STAT PATHWAY. IEC-SPECIFIC JAK/STAT PATHWAY DEREGULATION MAY BE, AT LEAST IN PART, RESPONSIBLE FOR INTESTINAL HOMEOSTASIS DISRUPTION IN MUTANT MICE. 2021 2 5566 33 ROLE OF INFLAMMATION IN THE DEVELOPMENT OF COLORECTAL CANCER. CHRONIC INFLAMMATION CAN LEAD TO THE DEVELOPMENT OF MANY DISEASES, INCLUDING CANCER. INFLAMMATORY BOWEL DISEASE (IBD) THAT INCLUDES BOTH ULCERATIVE COLITIS (UC) AND CROHNMP'S DISEASE (CD) ARE RISK FACTORS FOR THE DEVELOPMENT OF COLORECTAL CANCER (CRC). MANY CYTOKINES PRODUCED PRIMARILY BY THE GUT IMMUNE CELLS EITHER DURING OR IN RESPONSE TO LOCALIZED INFLAMMATION IN THE COLON AND RECTUM ARE KNOWN TO STIMULATE THE COMPLEX INTERACTIONS BETWEEN THE DIFFERENT CELL TYPES IN THE GUT ENVIRONMENT RESULTING IN ACUTE INFLAMMATION. SUBSEQUENTLY, CHRONIC INFLAMMATION, TOGETHER WITH GENETIC AND EPIGENETIC CHANGES, HAVE BEEN SHOWN TO LEAD TO THE DEVELOPMENT AND PROGRESSION OF CRC. VARIOUS CELL TYPES PRESENT IN THE COLON, SUCH AS ENTEROCYTES, PANETH CELLS, GOBLET CELLS, AND MACROPHAGES, EXPRESS RECEPTORS FOR INFLAMMATORY CYTOKINES AND RESPOND TO TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA), INTERLEUKIN-1 BETA (IL-1BETA), IL-6, AND OTHER CYTOKINES. AMONG THE SEVERAL CYTOKINES PRODUCED, TNF-ALPHA AND IL-1BETA ARE THE KEY PRO-INFLAMMATORY MOLECULES THAT PLAY CRITICAL ROLES IN THE DEVELOPMENT OF CRC. THE CURRENT REVIEW IS INTENDED TO CONSOLIDATE THE PUBLISHED FINDINGS TO FOCUS ON THE ROLE OF PRO-INFLAMMATORY CYTOKINES, NAMELY TNF-ALPHA AND IL-1BETA, ON INFLAMMATION (AND THE ALTERED IMMUNE RESPONSE) IN THE GUT, TO BETTER UNDERSTAND THE DEVELOPMENT OF CRC IN IBD, USING VARIOUS EXPERIMENTAL MODEL SYSTEMS, PRECLINICAL AND CLINICAL STUDIES. MOREOVER, THIS REVIEW ALSO HIGHLIGHTS THE CURRENT THERAPEUTIC STRATEGIES AVAILABLE (MONOTHERAPY AND COMBINATION THERAPY) TO ALLEVIATE THE SYMPTOMS OR TREAT INFLAMMATION-ASSOCIATED CRC BY USING MONOCLONAL ANTIBODIES OR APTAMERS TO BLOCK PRO-INFLAMMATORY MOLECULES, INHIBITORS OF TYROSINE KINASES IN THE INFLAMMATORY SIGNALING CASCADE, COMPETITIVE INHIBITORS OF PRO-INFLAMMATORY MOLECULES, AND THE NUCLEIC ACID DRUGS LIKE SMALL ACTIVATING RNAS (SARNAS) OR MICRORNA (MIRNA) MIMICS TO ACTIVATE TUMOR SUPPRESSOR OR REPRESS ONCOGENE/PRO-INFLAMMATORY CYTOKINE GENE EXPRESSION. 2021 3 5999 50 THE ACETYLOME REGULATORS HDAC1 AND HDAC2 DIFFERENTLY MODULATE INTESTINAL EPITHELIAL CELL DEPENDENT HOMEOSTATIC RESPONSES IN EXPERIMENTAL COLITIS. HISTONE DEACETYLASES (HDAC) REMOVE ACETYL GROUPS FROM PROTEINS, INFLUENCING GLOBAL AND SPECIFIC GENE EXPRESSION. HDACS CONTROL INFLAMMATION, AS SHOWN BY HDAC INHIBITOR-DEPENDENT PROTECTION FROM DEXTRAN SULFATE SODIUM (DSS)-INDUCED MURINE COLITIS. ALTHOUGH TISSUE-SPECIFIC HDAC KNOCKOUTS SHOW REDUNDANT AND SPECIFIC FUNCTIONS, LITTLE IS KNOWN OF THEIR INTESTINAL EPITHELIAL CELL (IEC) ROLE. WE HAVE SHOWN PREVIOUSLY THAT DUAL HDAC1/HDAC2 IEC-SPECIFIC LOSS DISRUPTS CELL PROLIFERATION AND DETERMINATION, WITH DECREASED SECRETORY CELL NUMBERS AND ALTERED BARRIER FUNCTION. WE THUS INVESTIGATED HOW COMPOUND HDAC1/HDAC2 OR HDAC2 IEC-SPECIFIC DEFICIENCY ALTERS THE INFLAMMATORY RESPONSE. FLOXED HDAC1 AND HDAC2 AND VILLIN-CRE MICE WERE INTERBRED. COMPOUND HDAC1/HDAC2 IEC-DEFICIENT MICE SHOWED CHRONIC BASAL INFLAMMATION, WITH INCREASED BASAL DISEASE ACTIVITY INDEX (DAI) AND DEREGULATED REG GENE COLONIC EXPRESSION. DSS-TREATED DUAL HDAC1/HDAC2 IEC-DEFICIENT MICE DISPLAYED INCREASED DAI, HISTOLOGICAL SCORE, INTESTINAL PERMEABILITY, AND INFLAMMATORY GENE EXPRESSION. IN CONTRAST TO DOUBLE KNOCKOUTS, HDAC2 IEC-SPECIFIC LOSS DID NOT AFFECT IEC DETERMINATION AND GROWTH, NOR RESULT IN CHRONIC INFLAMMATION. HOWEVER, HDAC2 DISRUPTION PROTECTED AGAINST DSS COLITIS, AS SHOWN BY DECREASED DAI, INTESTINAL PERMEABILITY AND CASPASE-3 CLEAVAGE. HDAC2 IEC-SPECIFIC DEFICIENT MICE DISPLAYED INCREASED EXPRESSION OF IEC GENE SUBSETS, SUCH AS COLONIC ANTIMICROBIAL REG3B AND REG3G MRNAS, AND DECREASED EXPRESSION OF IMMUNE CELL FUNCTION-RELATED GENES. OUR DATA SHOW THAT HDAC1 AND HDAC2 ARE ESSENTIAL IEC HOMEOSTASIS REGULATORS. IEC-SPECIFIC HDAC1 AND HDAC2 MAY ACT AS EPIGENETIC SENSORS AND TRANSMITTERS OF ENVIRONMENTAL CUES AND REGULATE IEC-MEDIATED MUCOSAL HOMEOSTATIC AND INFLAMMATORY RESPONSES. DIFFERENT LEVELS OF IEC HDAC ACTIVITY MAY LEAD TO POSITIVE OR NEGATIVE OUTCOMES ON INTESTINAL HOMEOSTASIS DURING INFLAMMATION. 2014 4 2065 28 EPIGENETIC CONTROL OF INTESTINAL BARRIER FUNCTION AND INFLAMMATION IN ZEBRAFISH. THE INTESTINAL EPITHELIUM FORMS A BARRIER PROTECTING THE ORGANISM FROM MICROBES AND OTHER PROINFLAMMATORY STIMULI. THE INTEGRITY OF THIS BARRIER AND THE PROPER RESPONSE TO INFECTION REQUIRES PRECISE REGULATION OF POWERFUL IMMUNE HOMING SIGNALS SUCH AS TUMOR NECROSIS FACTOR (TNF). DYSREGULATION OF TNF LEADS TO INFLAMMATORY BOWEL DISEASES (IBD), BUT THE MECHANISM CONTROLLING THE EXPRESSION OF THIS POTENT CYTOKINE AND THE EVENTS THAT TRIGGER THE ONSET OF CHRONIC INFLAMMATION ARE UNKNOWN. HERE, WE SHOW THAT LOSS OF FUNCTION OF THE EPIGENETIC REGULATOR UBIQUITIN-LIKE PROTEIN CONTAINING PHD AND RING FINGER DOMAINS 1 (UHRF1) IN ZEBRAFISH LEADS TO A REDUCTION IN TNFA PROMOTER METHYLATION AND THE INDUCTION OF TNFA EXPRESSION IN INTESTINAL EPITHELIAL CELLS (IECS). THE INCREASE IN IEC TNFA LEVELS IS MICROBE-DEPENDENT AND RESULTS IN IEC SHEDDING AND APOPTOSIS, IMMUNE CELL RECRUITMENT, AND BARRIER DYSFUNCTION, CONSISTENT WITH CHRONIC INFLAMMATION. IMPORTANTLY, TNFA KNOCKDOWN IN UHRF1 MUTANTS RESTORES IEC MORPHOLOGY, REDUCES CELL SHEDDING, AND IMPROVES BARRIER FUNCTION. WE PROPOSE THAT LOSS OF EPIGENETIC REPRESSION AND TNF INDUCTION IN THE INTESTINAL EPITHELIUM CAN LEAD TO IBD ONSET. 2015 5 4535 34 MULTIPLE ROLES OF TOLL-LIKE RECEPTOR 4 IN COLORECTAL CANCER. TOLL-LIKE RECEPTOR (TLR) SIGNALING HAS BEEN IMPLICATED IN THE INFLAMMATORY RESPONSES IN INTESTINAL EPITHELIAL CELLS (IECS). SUCH INFLAMMATORY SIGNALS MEDIATE COMPLEX INTERACTIONS BETWEEN COMMENSAL BACTERIA AND TLRS AND ARE REQUIRED FOR IEC PROLIFERATION, IMMUNE RESPONSE, REPAIR, AND HOMEOSTASIS. THE UPREGULATION OF CERTAIN TLRS IN COLORECTAL CANCER (CRC) TISSUES SUGGESTS THAT TLRS MAY PLAY AN ESSENTIAL ROLE IN THE PROGNOSIS OF CHRONIC AND INFLAMMATORY DISEASES THAT ULTIMATELY CULMINATE IN CRC. HERE, WE PROVIDE A COMPREHENSIVE REVIEW OF THE LITERATURE ON THE INVOLVEMENT OF THE TLR PATHWAY IN THE INITIATION, PROGRESSION, AND METASTASIS OF CRC, AS WELL AS INHERITED GENETIC VARIATION AND EPIGENETIC REGULATION. THE DIFFERENTIAL EXPRESSION OF TLRS IN EPITHELIAL CELLS HAS ALSO BEEN DISCUSSED. IN PARTICULAR, WE EMPHASIZE THE PHYSIOLOGICAL ROLE OF TLR4 IN CRC DEVELOPMENT AND PATHOGENESIS, AND PROPOSE NOVEL AND PROMISING APPROACHES FOR CRC THERAPEUTICS WITH THE AID OF TLR LIGANDS. 2014 6 4774 34 NUCLEIC ACID APTAMERS TARGETING EPIGENETIC REGULATORS: AN INNOVATIVE THERAPEUTIC OPTION. EPIGENETIC MECHANISMS INCLUDE DNA METHYLATION, POSTTRANSLATIONAL MODIFICATIONS OF HISTONES, CHROMATIN REMODELING FACTORS, AND POST TRANSCRIPTIONAL GENE REGULATION BY NONCODING RNAS. ALL TOGETHER, THESE PROCESSES REGULATE GENE EXPRESSION BY CHANGING CHROMATIN ORGANIZATION AND DNA ACCESSIBILITY. TARGETING ENZYMATIC REGULATORS RESPONSIBLE FOR DNA AND CHROMATIN MODIFICATIONS HOLD PROMISE FOR MODULATING THE TRANSCRIPTIONAL REGULATION OF GENES THAT ARE INVOLVED IN CANCER, AS WELL AS IN CHRONIC NONCOMMUNICABLE METABOLIC DISEASES LIKE OBESITY, DIABETES, AND CARDIOVASCULAR DISEASES. INCREASINGLY STUDIES ARE EMERGING, LEADING TO THE IDENTIFICATION OF SPECIFIC AND EFFECTIVE MOLECULES TARGETING EPIGENETIC PATHWAYS INVOLVED IN DISEASE ONSET. IN THIS REGARD, RNA INTERFERENCE, WHICH USES SMALL RNAS TO REDUCE GENE EXPRESSION AND NUCLEIC ACID APTAMERS ARE ARISING AS VERY PROMISING CANDIDATES IN THERAPEUTIC APPROACH. COMMON TO ALL THESE STRATEGIES IS THE IMPERATIVE CHALLENGE OF SPECIFICITY. IN THIS REGARD, NUCLEIC ACID APTAMERS HAVE EMERGED AS AN ATTRACTIVE CLASS OF CARRIER MOLECULES DUE TO THEIR ABILITY TO BIND WITH HIGH AFFINITY TO SPECIFIC LIGANDS, THEIR HIGH CHEMICAL FLEXIBILITY AS WELL AS TISSUE PENETRATION CAPABILITY. IN THIS REVIEW, WE WILL FOCUS ON THE RECENT PROGRESS IN THE FIELD OF APTAMERS USED AS TARGETING MOIETIES ABLE TO RECOGNIZE AND REVERT EPIGENETICS MARKS INVOLVED IN DISEASES ONSET. 2018 7 3804 29 INTESTINAL MICROBIOTA, CHRONIC INFLAMMATION, AND COLORECTAL CANCER. IN ADDITION TO GENETIC AND EPIGENETIC FACTORS, VARIOUS ENVIRONMENTAL FACTORS, INCLUDING DIET, PLAY IMPORTANT ROLES IN THE DEVELOPMENT OF COLORECTAL CANCER (CRC). RECENTLY, THERE IS INCREASING INTEREST IN THE INTESTINAL MICROBIOTA AS AN ENVIRONMENTAL RISK FACTOR FOR CRC, BECAUSE DIET ALSO INFLUENCES THE COMPOSITION OF THE INTESTINAL MICROBIOTA. THE HUMAN INTESTINAL MICROBIOTA COMPRISES ABOUT 100 TRILLION MICROBES. THIS MICROBIOME THRIVES ON UNDIGESTED DIETARY RESIDUES IN THE INTESTINAL LUMEN AND PRODUCES VARIOUS METABOLITES. IT IS WELL KNOWN THAT THE DIETARY RISK FACTORS FOR CRC ARE MEDIATED BY DYSBIOSIS OF THE INTESTINAL MICROBIOTA AND THEIR METABOLITES. IN THIS REVIEW, WE DESCRIBE THE BACTERIAL TAXA ASSOCIATED WITH CRC, INCLUDING FUSOBACTERIUM NUCLEATUM, ENTEROTOXIGENIC BACTEROIDES FRAGILIS, ESCHERICHIA COLI, AND BUTYRATE-PRODUCING BACTERIA. WE ALSO DISCUSS THE HOST-DIET INTERACTION IN COLORECTAL CARCINOGENESIS. 2018 8 5602 26 RORGAMMAT(+) HEMATOPOIETIC CELLS ARE NECESSARY FOR TUMOR CELL PROLIFERATION DURING COLITIS-ASSOCIATED TUMORIGENESIS IN MICE. COLORECTAL CANCER (CRC) IS ONE OF THE MOST COMMON TUMOR ENTITIES. IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES, THE DEVELOPMENT OF COLITIS-ASSOCIATED COLON CANCER IS CONSIDERED A DANGEROUS LONG-TERM COMPLICATION. IL-17A AND THE TRANSCRIPTION FACTOR RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR GAMMAT (RORGAMMAT) PLAY FUNDAMENTAL ROLES IN THE PATHOGENESIS OF INFLAMMATORY BOWEL DISEASES; IN HUMAN STUDIES, WE DETECTED A DENSE INFILTRATION OF RORGAMMAT-DEPENDENT CD4(+) IL17A(+) T HELPER (TH)17 CELLS IN SPECIMENS OF CRC, ULCERATIVE COLITIS, AND ULCERATIVE COLITIS-ASSOCIATED COLORECTAL CANCER. HOWEVER, THE MECHANISTIC ROLE OF RORGAMMAT(+) HEMATOPOIETIC CELLS IN COLITIS-ASSOCIATED TUMORIGENESIS REMAINS UNCLEAR. TO INVESTIGATE COLITIS-ASSOCIATED COLON TUMORIGENESIS, WE CONDUCTED STUDIES IN THE AOM+DSS MOUSE MODEL THAT REVEALED THE IMPORTANCE OF RORGAMMAT FOR COLON TUMOR PROGRESSION. IN THE ABSENCE OF RORGAMMAT-DEPENDENT TH17 LYMPHOCYTES, MICE SHOWED SIGNS OF INTENSE CHRONIC COLITIS, BUT DEVELOPED SIGNIFICANTLY FEWER MACROSCOPIC TUMOR NODULES. THE REDUCTION OF TUMOR DEVELOPMENT IN RORGAMMAT(-/-) MICE WAS NOT DUE TO REDUCED COLON TUMOR INITIATION. HOWEVER, THE PROLIFERATION RATE OF TUMOR CELLS WAS REDUCED IN THE ABSENCE OF RORGAMMAT-DEPENDENT TH17 CELLS AND TUMOR CELLS SHOWED PRONOUNCED SIGNS OF SENESCENCE-ASSOCIATED EPIGENETIC AND LYSOSOMAL CHANGES. THESE RESULTS INDICATE AN IMPORTANT ROLE FOR THE IMMUNOLOGICAL MILIEU IN COLITIS-ASSOCIATED CANCER, WHICH IS SHAPED IN-PART BY RORGAMMAT-DEPENDENT TH17 LYMPHOCYTES THAT SUPPORT CRC GROWTH. 2015 9 3853 23 IS MIR-223 UPREGULATION IN INFLAMMATORY BOWEL DISEASES A PROTECTIVE RESPONSE? INFLAMMATORY BOWEL DISEASES (IBD) ARE CHARACTERIZED BY CHRONIC INFLAMMATION AND DAMAGE OF COLONOCYTES WITH ETIOLOGY OF GENETIC, EPIGENETIC AND ENVIRONMENTAL FACTORS. MICRORNA-223 (MIR-223) HAS BEEN FOUND TO BE INCREASED IN BOTH IBD PATIENTS AND ANIMAL COLITIS MODELS. HOWEVER, CONTENTIOUS OPINIONS RELEVANT TO THE ROLES OF MIR-223 IN IBD HAVE BEEN REPORTED. NOTWITHSTADING THAT MOST STUDIES HAVE DESCRIBED THAT MIR-223 HAS ANTI-INFLAMMATORY EFFECTS, SEVERAL REPORTS HAVE PROGRESSED A PRO-INFLAMMATORY VIEW. IN THIS REVIEW, WE SUMMARISE BOTH THE ANTI-INFLAMMATORY AND PRO-INFLAMMATORY EFFECTS OF MIR-223 ON KEY MOLECULES IN INFLAMMATORY RESPONSES IN BOTH ANIMAL MODELS AND IN PATIENTS DIAGNOSED WITH IBD AND OBJECTIVELY DISCUSS THE POSSIBLE BASIS FOR THE DISCREPANCIES. 2023 10 3691 37 INFLAMMATORY BOWEL DISEASES: AN UPDATED OVERVIEW ON THE HEAT SHOCK PROTEIN INVOLVEMENT. INFLAMMATORY BOWEL DISEASES (IBDS) REPRESENT CHRONIC IDIOPATHIC DISORDERS, INCLUDING CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC), IN WHICH ONE OF THE TRIGGER FACTORS IS REPRESENTED BY ABERRANT IMMUNE INTERACTIONS BETWEEN THE INTESTINAL EPITHELIUM AND THE INTESTINAL MICROBIOTA. THE INVOLVEMENT OF HEAT SHOCK PROTEINS (HSPS) AS ETIOLOGICAL AND PATHOGENETIC FACTORS IS BECOMING OF INCREASING INTEREST. HSPS WERE FOUND TO BE DIFFERENTIALLY EXPRESSED IN THE INTESTINAL TISSUES AND SERA OF PATIENTS WITH CD AND UC. IT HAS BEEN SHOWN THAT HSPS CAN PLAY A DUAL ROLE IN THE DISEASE, DEPENDING ON THE STAGE OF PROGRESSION. THEY CAN SUPPORT THE INFLAMMATORY AND FIBROSIS PROCESS, BUT THEY CAN ALSO ACT AS PROTECTIVE FACTORS DURING DISEASE PROGRESSION OR BEFORE THE ONSET OF ONE OF THE WORST COMPLICATIONS OF IBD, COLORECTAL CANCER. FURTHERMORE, HSPS ARE ABLE TO MEDIATE THE INTERACTION BETWEEN THE INTESTINAL MICROBIOTA AND INTESTINAL EPITHELIAL CELLS. IN THIS WORK, WE DISCUSS THE INVOLVEMENT OF HSPS IN IBD CONSIDERING THEIR GENETIC, EPIGENETIC, IMMUNE AND MOLECULAR ROLES, REFERRING TO THE MOST RECENT WORKS PRESENT IN THE LITERATURE. WITH OUR REVIEW, WE WANT TO SHED LIGHT ON THE IMPORTANCE OF FURTHER EXPLORING THE ROLE OF HSPS, OR EVEN BETTER, THE ROLE OF THE MOLECULAR CHAPERONE SYSTEM (CS), IN IBD: VARIOUS MOLECULES OF THE CS INCLUDING HSPS MAY HAVE DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC POTENTIAL, PROMOTING THE CREATION OF NEW DRUGS THAT COULD OVERCOME THE SIDE-EFFECTS OF THE THERAPIES CURRENTLY USED. 2023 11 3701 24 INFLAMMATORY RESPONSE TO REGULATED CELL DEATH IN GOUT AND ITS FUNCTIONAL IMPLICATIONS. GOUT, A CHRONIC INFLAMMATORY ARTHRITIS DISEASE, IS CHARACTERIZED BY HYPERURICEMIA AND CAUSED BY INTERACTIONS BETWEEN GENETIC, EPIGENETIC, AND METABOLIC FACTORS. ACUTE GOUT SYMPTOMS ARE TRIGGERED BY THE INFLAMMATORY RESPONSE TO MONOSODIUM URATE CRYSTALS, WHICH IS MEDIATED BY THE INNATE IMMUNE SYSTEM AND IMMUNE CELLS (E.G., MACROPHAGES AND NEUTROPHILS), THE NACHT, LRR, AND PYD DOMAINS-CONTAINING PROTEIN 3 (NLRP3) INFLAMMASOME ACTIVATION, AND PRO-INFLAMMATORY CYTOKINE (E.G., IL-1BETA) RELEASE. RECENT STUDIES HAVE INDICATED THAT THE MULTIPLE PROGRAMMED CELL DEATH PATHWAYS INVOLVED IN THE INFLAMMATORY RESPONSE INCLUDE PYROPTOSIS, NETOSIS, NECROPTOSIS, AND APOPTOSIS, WHICH INITIATE INFLAMMATORY REACTIONS. IN THIS REVIEW, WE EXPLORE THE CORRELATION AND INTERACTIONS AMONG THESE FACTORS AND THEIR ROLES IN THE PATHOGENESIS OF GOUT TO PROVIDE FUTURE RESEARCH DIRECTIONS AND POSSIBILITIES FOR IDENTIFYING POTENTIAL NOVEL THERAPEUTIC TARGETS AND ENHANCING OUR UNDERSTANDING OF GOUT PATHOGENESIS. 2022 12 5907 35 TARGET-BASED SMALL MOLECULE DRUG DISCOVERY TOWARDS NOVEL THERAPEUTICS FOR INFLAMMATORY BOWEL DISEASES. INFLAMMATORY BOWEL DISEASE (IBD), INCLUDING ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD), IS A CLASS OF SEVERE AND CHRONIC DISEASES OF THE GASTROINTESTINAL (GI) TRACT WITH RECURRENT SYMPTOMS AND SIGNIFICANT MORBIDITY. LONG-TERM PERSISTENCE OF CHRONIC INFLAMMATION IN IBD IS A MAJOR CONTRIBUTING FACTOR TO NEOPLASTIC TRANSFORMATION AND THE DEVELOPMENT OF COLITIS-ASSOCIATED COLORECTAL CANCER. CONVERSELY, PERSISTENCE OF TRANSMURAL INFLAMMATION IN CD IS ASSOCIATED WITH FORMATION OF FIBROSING STRICTURES, RESULTING IN SUBSTANTIAL MORBIDITY. THE RECENT INTRODUCTION OF BIOLOGICAL RESPONSE MODIFIERS AS IBD THERAPIES, SUCH AS ANTIBODIES NEUTRALIZING TUMOR NECROSIS FACTOR (TNF)-ALPHA, HAVE REPLACED NONSELECTIVE ANTI-INFLAMMATORY CORTICOSTEROIDS IN DISEASE MANAGEMENT. HOWEVER, A LARGE PROPORTION (~40%) OF PATIENTS WITH THE TREATMENT OF ANTI-TNF-ALPHA ANTIBODIES ARE DISCONTINUED OR WITHDRAWN FROM THERAPY BECAUSE OF (1) PRIMARY NONRESPONSE, (2) SECONDARY LOSS OF RESPONSE, (3) OPPORTUNISTIC INFECTION, OR (4) ONSET OF CANCER. THEREFORE, THE DEVELOPMENT OF NOVEL AND EFFECTIVE THERAPEUTICS TARGETING SPECIFIC SIGNALING PATHWAYS IN THE PATHOGENESIS OF IBD IS URGENTLY NEEDED. IN THIS COMPREHENSIVE REVIEW, WE SUMMARIZE THE RECENT ADVANCES IN DRUG DISCOVERY OF NEW SMALL MOLECULES IN PRECLINICAL OR CLINICAL DEVELOPMENT FOR TREATING IBD THAT TARGET BIOLOGICALLY RELEVANT PATHWAYS IN MUCOSAL INFLAMMATION. THESE INCLUDE INTRACELLULAR ENZYMES (JANUS KINASES, RECEPTOR INTERACTING PROTEIN, PHOSPHODIESTERASE 4, IKAPPAB KINASE), INTEGRINS, G PROTEIN-COUPLED RECEPTORS (S1P, CCR9, CXCR4, CB2) AND INFLAMMASOME MEDIATORS (NLRP3), ETC. WE WILL ALSO DISCUSS EMERGING EVIDENCE OF A DISTINCT MECHANISM OF ACTION, BROMODOMAIN-CONTAINING PROTEIN 4, AN EPIGENETIC REGULATOR OF PATHWAYS INVOLVED IN THE ACTIVATION, COMMUNICATION, AND TRAFFICKING OF IMMUNE CELLS. WE HIGHLIGHT THEIR CHEMOTYPES, MODE OF ACTIONS, STRUCTURE-ACTIVITY RELATIONSHIPS, CHARACTERIZATIONS, AND THEIR IN VITRO/IN VIVO ACTIVITIES AND THERAPEUTIC POTENTIAL. THE PERSPECTIVES ON THE RELEVANT CHALLENGES, NEW OPPORTUNITIES, AND FUTURE DIRECTIONS IN THIS FIELD ARE ALSO DISCUSSED. 2021 13 3411 33 HP1GAMMA PREVENTS ACTIVATION OF THE CGAS/STING PATHWAY BY PRESERVING NUCLEAR ENVELOPE AND GENOMIC INTEGRITY IN COLON ADENOCARCINOMA CELLS. CHRONIC INFLAMMATORY PROCESSES IN THE INTESTINE RESULT IN SERIOUS CONDITIONS SUCH AS INFLAMMATORY BOWEL DISEASE (IBD) AND CANCER. AN INCREASED DETECTION OF CYTOPLASMIC DNA SENSORS HAS BEEN REPORTED IN THE IBD COLON MUCOSA, SUGGESTING THEIR CONTRIBUTION IN MUCOSAL INFLAMMATION. YET, THE MECHANISMS ALTERING DNA HOMEOSTASIS AND TRIGGERING THE ACTIVATION OF DNA SENSORS REMAIN POORLY UNDERSTOOD. IN THIS STUDY, WE SHOW THAT THE EPIGENETIC REGULATOR HP1GAMMA PLAYS A ROLE IN PRESERVING NUCLEAR ENVELOPE AND GENOMIC INTEGRITY IN ENTEROCYTIC CELLS, THEREBY PROTECTING AGAINST THE PRESENCE OF CYTOPLASMIC DNA. ACCORDINGLY, HP1 LOSS OF FUNCTION LED TO THE INCREASED DETECTION OF CGAS/STING, A CYTOPLASMIC DNA SENSOR THAT TRIGGERS INFLAMMATION. THUS, IN ADDITION TO ITS ROLE AS A TRANSCRIPTIONAL SILENCER, HP1GAMMA MAY ALSO EXERT ANTI-INFLAMMATORY PROPERTIES BY PREVENTING THE ACTIVATION OF THE ENDOGENOUS CYTOPLASMIC DNA RESPONSE IN THE GUT EPITHELIUM. 2023 14 312 36 ALCOHOL FEEDING IN MICE PROMOTES COLONIC HYPERPERMEABILITY AND CHANGES IN COLONIC ORGANOID STEM CELL FATE. BACKGROUND: ALCOHOL INCREASES INTESTINAL PERMEABILITY TO PROINFLAMMATORY MICROBIAL PRODUCTS THAT PROMOTE LIVER DISEASE, EVEN AFTER A PERIOD OF SOBRIETY. WE SOUGHT TO TEST THE HYPOTHESIS THAT ALCOHOL AFFECTS INTESTINAL STEM CELLS USING AN IN VIVO MODEL AND EX VIVO ORGANOIDS GENERATED FROM JEJUNUM AND COLON FROM MICE FED CHRONIC ALCOHOL. METHODS: MICE WERE FED A CONTROL OR AN ALCOHOL DIET. INTESTINAL PERMEABILITY, LIVER STEATOSIS-INFLAMMATION, AND STOOL SHORT-CHAIN FATTY ACIDS (SCFAS) WERE MEASURED. JEJUNUM AND COLONIC ORGANOIDS AND TISSUE WERE STAINED FOR STEM CELL, CELL LINEAGE, AND APICAL JUNCTION MARKERS WITH ASSESSMENT OF MRNA BY PCR AND RNA-SEQ. CHIP-PCR ANALYSIS WAS CARRIED OUT FOR NOTCH1 USING AN ANTIBODY SPECIFIC FOR ACETYLATED HISTONE 3. RESULTS: ALCOHOL-FED MICE EXHIBITED COLONIC (BUT NOT SMALL INTESTINAL) HYPERPERMEABILITY, STEATOHEPATITIS, AND DECREASED BUTYRATE/TOTAL SCFA RATIO IN STOOL. STEM CELL, CELL LINEAGE, AND APICAL JUNCTION MARKER STAINING IN TISSUE OR ORGANOIDS FROM JEJUNUM TISSUE WERE NOT IMPACTED BY ALCOHOL. ONLY CHROMOGRANIN A (CHGA) WAS INCREASED IN JEJUNUM ORGANOIDS BY QPCR. HOWEVER, COLONIC TISSUE AND ORGANOID STAINING EXHIBITED AN ALCOHOL-INDUCED SIGNIFICANT DECREASE IN CYTOKERATIN 20+ (KRT20+) ABSORPTIVE LINEAGE ENTEROCYTES, A DECREASE IN OCCLUDIN AND E-CADHERIN APICAL JUNCTION PROTEINS, AN INCREASE IN CHGA, AND AN INCREASE IN THE LGR5 STEM CELL MARKER. QPCR REVEALED AN ALCOHOL-INDUCED DECREASE IN COLONIC ORGANOID AND TISSUE NOTCH1, HES1, AND KRT20 AND INCREASED CHGA, SUPPORTING AN ALTERATION IN STEM CELL FATE DUE TO DECREASED NOTCH1 EXPRESSION. COLONIC TISSUE CHIP-PCR REVEALED ALCOHOL FEEDING SUPPRESSED NOTCH1 MRNA EXPRESSION (VIA DEACETYLATION OF HISTONE H3) AND DECREASED NOTCH1 TISSUE STAINING. CONCLUSIONS: DATA SUPPORT A MODEL FOR ALCOHOL-INDUCED COLONIC HYPERPERMEABILITY VIA EPIGENETIC EFFECTS ON NOTCH1, AND THUS HES1, SUPPRESSION THROUGH A MECHANISM INVOLVING HISTONE H3 DEACETYLATION AT THE NOTCH1 LOCUS. THIS DECREASED ENTEROCYTE AND INCREASED ENTEROENDOCRINE CELL COLONIC STEM CELL FATE AND DECREASED APICAL JUNCTIONAL PROTEINS LEADING TO HYPERPERMEABILITY. 2017 15 3218 44 HELICOBACTER INFECTION IS REQUIRED FOR INFLAMMATION AND COLON CANCER IN SMAD3-DEFICIENT MICE. ACCUMULATING EVIDENCE SUGGESTS THAT INTESTINAL MICROBIAL ORGANISMS MAY PLAY AN IMPORTANT ROLE IN TRIGGERING AND SUSTAINING INFLAMMATION IN INDIVIDUALS AFFLICTED WITH INFLAMMATORY BOWEL DISEASE (IBD). MOREOVER, INDIVIDUALS WITH IBD ARE AT INCREASED RISK FOR DEVELOPING COLORECTAL CANCER, SUGGESTING THAT CHRONIC INFLAMMATION MAY INITIATE GENETIC OR EPIGENETIC CHANGES ASSOCIATED WITH CANCER DEVELOPMENT. WE TESTED THE HYPOTHESIS THAT BACTERIA MAY CONTRIBUTE TO THE DEVELOPMENT OF COLON CANCER BY SYNERGIZING WITH DEFECTIVE TRANSFORMING GROWTH FACTOR-BETA (TGF-BETA) SIGNALING, A PATHWAY COMMONLY MUTATED IN HUMAN COLON CANCER. ALTHOUGH OTHERS HAVE REPORTED THAT MICE DEFICIENT IN THE TGF-BETA SIGNALING MOLECULE SMAD3 DEVELOP COLON CANCER, WE FOUND THAT SMAD3-DEFICIENT MICE MAINTAINED FREE OF THE GRAM-NEGATIVE ENTEROHEPATIC BACTERIA HELICOBACTER SPP. FOR UP TO 9 MONTHS DO NOT DEVELOP COLON CANCER. FURTHERMORE, INFECTION OF SMAD3(-/-) MICE WITH HELICOBACTER TRIGGERS COLON CANCER IN 50% TO 66% OF THE ANIMALS. USING REAL-TIME PCR, WE FOUND THAT HELICOBACTER ORGANISMS CONCENTRATE IN THE CECUM, THE PREFERRED SITE OF TUMOR DEVELOPMENT. MUCINOUS ADENOCARCINOMAS DEVELOP 5 TO 30 WEEKS AFTER INFECTION AND ARE PRECEDED BY AN EARLY INFLAMMATORY PHASE, CONSISTING OF INCREASED PROLIFERATION OF EPITHELIAL CELLS; INCREASED NUMBERS OF CYCLOOXYGENASE-2-POSITIVE CELLS, CD4(+) T CELLS, MACROPHAGES; AND INCREASED MHC CLASS II EXPRESSION. COLONIC TISSUE REVEALED INCREASED TRANSCRIPTS FOR THE ONCOGENE C-MYC AND THE PROINFLAMMATORY CYTOKINES INTERLEUKIN-1ALPHA (IL-1ALPHA), IL-1BETA, IL-6, IFN-GAMMA, AND TUMOR NECROSIS FACTOR-ALPHA, SOME OF WHICH HAVE BEEN IMPLICATED IN COLON CANCER. THESE RESULTS SUGGEST THAT BACTERIA MAY BE IMPORTANT IN TRIGGERING COLORECTAL CANCER, NOTABLY IN THE CONTEXT OF GENE MUTATIONS IN THE TGF-BETA SIGNALING PATHWAY, ONE OF THE MOST COMMONLY AFFECTED CELLULAR PATHWAYS IN COLORECTAL CANCER IN HUMANS. 2006 16 4274 29 MICROBIOTA IN INFLAMMATORY BOWEL DISEASE PATHOGENESIS AND THERAPY: IS IT ALL ABOUT DIET? INFLAMMATORY BOWEL DISEASE (IBD), INCLUDING ULCERATIVE COLITIS, CROHN'S DISEASE, AND UNCLASSIFIED IBD, CONTINUES TO CAUSE SIGNIFICANT MORBIDITY. WHILE ITS INCIDENCE IS INCREASING, NO CLEAR ETIOLOGY AND NO CURE HAVE YET BEEN DISCOVERED. RECENT FINDINGS SUGGEST THAT IBD MAY HAVE A MULTIFACTORIAL ETIOLOGY, WHERE COMPLEX INTERACTIONS BETWEEN GENETICS, EPIGENETICS, ENVIRONMENTAL FACTORS (INCLUDING DIET BUT ALSO INFECTIONS, ANTIBIOTICS, AND SANITATION), AND HOST IMMUNE SYSTEM LEAD TO ABNORMAL IMMUNE RESPONSES AND CHRONIC INFLAMMATION. OVER THE PAST YEARS, THE ROLE OF ALTERED GUT MICROBIOTA (IN BOTH COMPOSITION AND FUNCTION) IN IBD PATHOGENESIS HAS EMERGED AS AN OUTSTANDING AREA OF INTEREST. ACCORDING TO NEW FINDINGS, GUT DYSBIOSIS MAY APPEAR AS A KEY ELEMENT IN INITIATION OF INFLAMMATION IN IBD AND ITS COMPLICATIONS. MOREOVER, COMPLEX METAGENOMIC STUDIES PROVIDE POSSIBILITIES TO DISTINGUISH BETWEEN IBD TYPES AND APPRECIATE SEVERITY AND PROGNOSIS OF THE DISEASE, AS WELL AS RESPONSE TO THERAPY. THIS REVIEW PROVIDES AN UPDATED KNOWLEDGE OF RECENT FINDINGS LINKING ALTERED BACTERIAL COMPOSITION AND FUNCTIONS, VIRUSES, AND FUNGI TO IBD PATHOGENESIS. IT ALSO HIGHLIGHTS THE COMPLEX GENETIC, EPIGENETIC, IMMUNE, AND MICROBIAL INTERACTIONS IN RELATION TO ENVIRONMENTAL FACTORS (INCLUDING DIET). WE OVERVIEW THE ACTUAL OPTIONS TO MANIPULATE THE ALTERED MICROBIOTA, SUCH AS MODIFIED DIET, PROBIOTICS, PREBIOTICS, SYNBIOTICS, ANTIBIOTICS, AND FECAL TRANSPLANTATION. FUTURE POSSIBLE THERAPIES ARE ALSO INCLUDED. TARGETING ALTERED MICROBIOTA COULD BE THE NEXT THERAPEUTIC PERSONALIZED APPROACH, BUT MORE RESEARCH AND WELL-DESIGNED COMPARATIVE PROSPECTIVE STUDIES ARE REQUIRED TO FORMULATE ADEQUATE DIRECTIONS FOR PREVENTION AND THERAPY. 2015 17 4732 40 NOVEL BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE AND COLORECTAL CANCER: AN INTERPLAY BETWEEN METABOLIC DYSREGULATION AND EXCESSIVE INFLAMMATION. PERSISTENT INFLAMMATION CAN TRIGGER ALTERED EPIGENETIC, INFLAMMATORY, AND BIOENERGETIC STATES. INFLAMMATORY BOWEL DISEASE (IBD) IS AN IDIOPATHIC DISEASE CHARACTERIZED BY CHRONIC INFLAMMATION OF THE GASTROINTESTINAL TRACT, WITH EVIDENCE OF SUBSEQUENT METABOLIC SYNDROME DISORDER. STUDIES HAVE DEMONSTRATED THAT AS MANY AS 42% OF PATIENTS WITH ULCERATIVE COLITIS (UC) WHO ARE FOUND TO HAVE HIGH-GRADE DYSPLASIA, EITHER ALREADY HAD COLORECTAL CANCER (CRC) OR DEVELOP IT WITHIN A SHORT TIME. THE PRESENCE OF LOW-GRADE DYSPLASIA IS ALSO PREDICTIVE OF CRC. MANY SIGNALING PATHWAYS ARE SHARED AMONG IBD AND CRC, INCLUDING CELL SURVIVAL, CELL PROLIFERATION, ANGIOGENESIS, AND INFLAMMATORY SIGNALING PATHWAYS. CURRENT IBD THERAPEUTICS TARGET A SMALL SUBSET OF MOLECULAR DRIVERS OF IBD, WITH MANY FOCUSED ON THE INFLAMMATORY ASPECT OF THE PATHWAYS. THUS, THERE IS A GREAT NEED TO IDENTIFY BIOMARKERS OF BOTH IBD AND CRC, THAT CAN BE PREDICTIVE OF THERAPEUTIC EFFICACY, DISEASE SEVERITY, AND PREDISPOSITION TO CRC. IN THIS STUDY, WE EXPLORED THE CHANGES IN BIOMARKERS SPECIFIC FOR INFLAMMATORY, METABOLIC, AND PROLIFERATIVE PATHWAYS, TO HELP DETERMINE THE RELEVANCE TO BOTH IBD AND CRC. OUR ANALYSIS DEMONSTRATED, FOR THE FIRST TIME IN IBD, THE LOSS OF THE TUMOR SUPPRESSOR PROTEIN RAS ASSOCIATED FAMILY PROTEIN 1A (RASSF1A), VIA EPIGENETIC CHANGES, THE HYPERACTIVATION OF THE OBLIGATE KINASE OF THE NOD2 PATHOGEN RECOGNITION RECEPTOR (RECEPTOR INTERACTING PROTEIN KINASE 2 [RIPK2]), THE LOSS OF ACTIVATION OF THE METABOLIC KINASE, AMP ACTIVATED PROTEIN KINASE (AMPKALPHA1), AND, LASTLY, THE ACTIVATION OF THE TRANSCRIPTION FACTOR AND KINASE YES ASSOCIATED PROTEIN (YAP) KINASE, THAT IS INVOLVED IN PROLIFERATION OF CELLS. THE EXPRESSION AND ACTIVATION STATUS OF THESE FOUR ELEMENTS ARE MIRRORED IN IBD, CRC, AND IBD-CRC PATIENTS AND, IMPORTANTLY, IN MATCHED BLOOD AND BIOPSY SAMPLES. THE LATTER WOULD SUGGEST THAT BIOMARKER ANALYSIS CAN BE PERFORMED NON-INVASIVELY, TO UNDERSTAND IBD AND CRC, WITHOUT THE NEED FOR INVASIVE AND COSTLY ENDOSCOPIC ANALYSIS. THIS STUDY, FOR THE FIRST TIME, ILLUSTRATES THE NEED TO UNDERSTAND IBD OR CRC BEYOND AN INFLAMMATORY PERSPECTIVE AND THE VALUE OF THERAPEUTICS DIRECTED TO RESET ALTERED PROLIFERATIVE AND METABOLIC STATES WITHIN THE COLON. THE USE OF SUCH THERAPEUTICS MAY TRULY DRIVE PATIENTS INTO REMISSION. 2023 18 3920 26 LINKING IMMUNITY, EPIGENETICS, AND CANCER IN INFLAMMATORY BOWEL DISEASE. MOST OF WHAT IS KNOWN ABOUT THE PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE (IBD) PERTAINS TO COMPLEX INTERPLAY BETWEEN HOST GENETICS, IMMUNITY, AND ENVIRONMENTAL FACTORS. EPIGENETIC MODIFICATIONS PLAY PIVOTAL ROLES IN INTESTINAL IMMUNITY AND MUCOSAL HOMEOSTASIS AS WELL AS MEDIATING GENE-ENVIRONMENT INTERACTIONS. IN THIS ARTICLE, WE PROVIDE A HISTORICAL ACCOUNT OF EPIGENETIC RESEARCH EITHER DIRECTLY RELATED OR PERTINENT TO THE PATHOGENESIS AND MANAGEMENT OF IBD. WE FURTHER COLLATE EMERGING EVIDENCE SUPPORTING ROLES FOR EPIGENETIC MECHANISMS IN RELEVANT ASPECTS OF IBD BIOLOGY, INCLUDING DEREGULATED IMMUNITY, HOST-PATHOGEN RECOGNITION AND MUCOSAL INTEGRITY. FINALLY, WE HIGHLIGHT KEY EPIGENETIC MECHANISMS THAT LINK CHRONIC INFLAMMATION TO SPECIFIC IBD COMORBIDITIES, INCLUDING COLITIS-ASSOCIATED CANCER AND DISCUSS THEIR POTENTIAL UTILITY AS NOVEL BIOMARKERS OR PHARMACOLOGIC TARGETS IN IBD THERAPY. 2014 19 4365 25 MIRNA MOLECULES-LATE BREAKING TREATMENT FOR INFLAMMATORY BOWEL DISEASES? MICRORNAS (MIRNAS) ARE A GROUP OF NON-CODING RNAS THAT PLAY A CRITICAL ROLE IN REGULATING EPIGENETIC MECHANISMS IN INFLAMMATION-RELATED DISEASES. INFLAMMATORY BOWEL DISEASES (IBDS), WHICH PRIMARILY INCLUDE ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD), ARE CHARACTERIZED BY CHRONIC RECURRENT INFLAMMATION OF INTESTINAL TISSUES. DUE TO THE MULTIFACTORIAL ETIOLOGY OF THESE DISEASES, THE DEVELOPMENT OF INNOVATIVE TREATMENT STRATEGIES THAT CAN EFFECTIVELY MAINTAIN REMISSION AND ALLEVIATE DISEASE SYMPTOMS IS A MAJOR CHALLENGE. IN RECENT YEARS, EVIDENCE FOR THE REGULATORY ROLE OF MIRNAS IN THE PATHOGENETIC MECHANISMS OF VARIOUS DISEASES, INCLUDING IBD, HAS BEEN ACCUMULATING. IN LIGHT OF THESE FINDINGS, MIRNAS REPRESENT POTENTIAL INNOVATIVE CANDIDATES FOR THERAPEUTIC APPLICATION IN IBD. IN THIS REVIEW, WE DISCUSS RECENT FINDINGS ON THE ROLE OF MIRNAS IN REGULATING INFLAMMATORY RESPONSES, MAINTAINING INTESTINAL BARRIER INTEGRITY, AND DEVELOPING FIBROSIS IN CLINICAL AND EXPERIMENTAL IBD. THE FOCUS IS ON THE EXISTING LITERATURE, INDICATING POTENTIAL THERAPEUTIC APPLICATION OF MIRNAS IN BOTH PRECLINICAL EXPERIMENTAL IBD MODELS AND TRANSLATIONAL DATA IN THE CONTEXT OF CLINICAL IBD. TO DATE, A LARGE AND DIVERSE DATA SET, WHICH IS GROWING RAPIDLY, SUPPORTS THE POTENTIAL USE OF MIRNA-BASED THERAPIES IN CLINICAL PRACTICE, ALTHOUGH MANY QUESTIONS REMAIN UNANSWERED. 2023 20 2233 39 EPIGENETIC MODIFICATIONS OF THE NUCLEAR FACTOR KAPPA B SIGNALLING PATHWAY AND ITS IMPACT ON INFLAMMATORY BOWEL DISEASE. BACKGROUND: INFLAMMATORY BOWEL DISEASE (IBD) IS A MULTIFACTORIAL CONDITION INFLUENCED BY THE IMMUNE SYSTEM, THE INTESTINAL MICROBIOTA, ENVIRONMENTAL FACTORS, GENETIC AND EPIGENETIC FACTORS. GENETIC- AND ENVIRONMENT- INDUCED DYSREGULATION OF THE NUCLEAR FACTOR-KAPPA B (NF-KAPPAB) TRANSCRIPTION FACTOR PATHWAY HAS BEEN LINKED TO IBD PATHOGENESIS. OBJECTIVE: TO ASSESS THE CURRENT EVIDENCE IN RELATION TO THE CONTRIBUTION OF THE CLASSICAL AND ALTERNATIVE NF-KAPPAB PATHWAYS IN IBD AND TO DISCUSS THE EPIGENETIC MECHANISMS THAT IMPACT ON NF-KAPPAB FUNCTION. METHODS: A MEDLINE SEARCH FOR 'NF-KAPPAB/NF-KAPPAB', IN COMBINATION WITH TERMS INCLUDING 'INFLAMMATORY BOWEL DISEASE/IBD', 'INTESTINAL INFLAMMATION', 'CROHN'S DISEASE', 'ULCERATIVE COLITIS', 'COLITIS'; 'EPIGENETICS', 'DNA METHYLATION', 'HISTONES', 'MICRORNAS/MIRNAS' AND 'SHORT NON-CODING/LONG NON-CODING RNAS' WAS PERFORMED. RESULTS: BOTH NF-KAPPAB PATHWAYS CONTRIBUTE TO THE CHRONIC INFLAMMATION UNDERLYING IBD BY REGULATING THE INFLAMMATORY IMMUNE RESPONSES AND HOMEOSTASIS OF THE INTESTINAL EPITHELIUM (CLASSICAL PATHWAY) OR REGULATING BOWEL INFLAMMATION AND EPITHELIAL MICROFOLD (M) CELL FUNCTION (ALTERNATIVE PATHWAY). DNA METHYLATION IS A COMMON EPIGENETIC MODIFICATION IN INTESTINAL INFLAMMATION, INCLUDING NFKB1 AND RELA LOCI. CONVERSELY, LITTLE IS UNDERSTOOD REGARDING EPIGENETIC EFFECTS ON GENES ENCODING OTHER NF-KAPPAB SUBUNITS, PARTICULARLY THOSE OF THE ALTERNATIVE PATHWAY, AND IN THE CONTEXT OF IBD. HOWEVER, NF-KAPPAB INTERACTION WITH CHROMATIN MODIFIERS IS ALSO SEEN TO BE AN ESSENTIAL MECHANISM OF REGULATION OF DOWNSTREAM TARGET GENES RELEVANT TO NF-KAPPAB-MEDIATED INFLAMMATORY RESPONSES. CONCLUSION: FURTHER RESEARCH IS CLEARLY WARRANTED IN THIS AREA, AS UNDERSTANDING THE CELL-SPECIFIC REGULATION OF THE NF-KAPPAB PATHWAYS WILL BRING RESEARCHERS INTO A POSITION TO ACHIEVE MORE EFFICIENT STRATIFICATION OF IBD PATIENTS, AND MORE TARGETED AND EFFECTIVE CHOICE OF TREATMENT. 2021